Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,754,990
  • Shares Outstanding, K 397,957
  • Annual Sales, $ 930 K
  • Annual Income, $ -346,790 K
  • 60-Month Beta 2.02
  • Price/Sales 1,700.05
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IBRX with:

Options Overview Details

View History
  • Implied Volatility 111.31% ( -10.73%)
  • Historical Volatility 120.95%
  • IV Percentile 54%
  • IV Rank 14.57%
  • IV High 322.16% on 06/17/22
  • IV Low 75.36% on 11/09/21
  • Put/Call Vol Ratio 0.92
  • Today's Volume 251
  • Volume Avg (30-Day) 455
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 36,837
  • Open Int (30-Day) 36,158

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.23
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.84 +57.22%
on 06/14/22
4.83 -7.56%
on 07/06/22
+0.90 (+25.07%)
since 06/06/22
3-Month
2.60 +71.73%
on 05/12/22
5.59 -20.13%
on 04/07/22
-1.13 (-20.13%)
since 04/06/22
52-Week
2.60 +71.73%
on 05/12/22
13.42 -66.73%
on 07/07/21
-8.97 (-66.75%)
since 07/06/21

Most Recent Stories

More News
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

ImmunityBio, Inc. ( NASDAQ: IBRX ), a leading clinical-stage immunotherapy company, today announced new positive data from the company’s pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive...

IBRX : 4.48 (+1.59%)
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803,...

IBRX : 4.48 (+1.59%)
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting,...

IBRX : 4.48 (+1.59%)
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for...

IBRX : 4.48 (+1.59%)
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance...

ASEP.CN : 0.155 (-54.41%)
SEPSF : 0.2013 (+0.65%)
IBRX : 4.48 (+1.59%)
DVAX : 13.90 (-0.86%)
ALLO : 11.50 (-2.21%)
ENSC : 0.5755 (-1.27%)
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months...

IBRX : 4.48 (+1.59%)
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market

Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary –  The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years....

GDBYF : 0.0171 (-10.94%)
GDBY.CN : 0.025 (unch)
LH : 241.24 (+0.52%)
DGX : 134.87 (+0.97%)
IBRX : 4.48 (+1.59%)
MRNA : 157.07 (+0.98%)
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility

BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.4834 (-1.35%)
IBRX : 4.48 (+1.59%)
ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced the successful completion of its acquisition of the leasehold interest in an ISO Class 5 pharmaceutical...

IBRX : 4.48 (+1.59%)
ATNX : 0.4834 (-1.35%)
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive data from the company’s late-stage bladder cancer trial (QUILT-3.032). The data showed sustained complete...

IBRX : 4.48 (+1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 5.23
2nd Resistance Point 4.84
1st Resistance Point 4.62
Last Price 4.48
1st Support Level 4.01
2nd Support Level 3.62
3rd Support Level 3.40

See More

52-Week High 13.42
Fibonacci 61.8% 9.29
Fibonacci 50% 8.01
Fibonacci 38.2% 6.73
Last Price 4.48
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar